A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Urothelial Carcinoma|Triple Negative Breast Cancer|Non-small Cell Lung Cancer|Squamous Cell Carcinoma of Head and Neck|Hormone Receptor-positive/HER2-negative Breast Cancer
Interventions: DRUG: SBT6290|DRUG: SBT6290|DRUG: pembrolizumab
Sponsor: Silverback Therapeutics